Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Cipla Ltd ( (IN:CIPLA) ) is now available.
Cipla Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the processing of dematerialization requests for the quarter ending September 30, 2025. This announcement underscores Cipla’s compliance with regulatory requirements, ensuring that its securities are properly managed and listed on the relevant stock exchanges, thereby maintaining transparency and trust with its stakeholders.
More about Cipla Ltd
Cipla Ltd is a leading pharmaceutical company based in India, known for its extensive range of pharmaceutical products and services. The company focuses on the development and manufacturing of medicines to treat respiratory, cardiovascular, and other chronic diseases, making significant contributions to the healthcare industry.
Average Trading Volume: 51,685
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1274.5B INR
For an in-depth examination of CIPLA stock, go to TipRanks’ Overview page.